Top ▲

NK3 receptor

Click here for help

Target id: 362

Nomenclature: NK3 receptor

Family: Tachykinin receptors

Contents:

Gene and Protein Information Click here for help
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 465 4q24 TACR3 tachykinin receptor 3 50
Mouse 7 452 3 G3 Tacr3 tachykinin receptor 3 100
Rat 7 452 2q43 Tacr3 tachykinin receptor 3 88
Previous and Unofficial Names Click here for help
Neurokinin B receptor | neurokinin beta receptor | Nmkr | Tac3r | neuromedin K receptor | NK-3 receptor | SP-N receptor
Database Links Click here for help
Specialist databases
GPCRdb nk3r_human (Hs), nk3r_mouse (Mm), nk3r_rat (Rn)
Other databases
Alphafold P29371 (Hs), P47937 (Mm), P16177 (Rn)
ChEMBL Target CHEMBL4429 (Hs), CHEMBL3154 (Rn)
Ensembl Gene ENSG00000169836 (Hs), ENSMUSG00000028172 (Mm), ENSRNOG00000009372 (Rn)
Entrez Gene 6870 (Hs), 21338 (Mm), 24808 (Rn)
Human Protein Atlas ENSG00000169836 (Hs)
KEGG Gene hsa:6870 (Hs), mmu:21338 (Mm), rno:24808 (Rn)
OMIM 162332 (Hs)
Orphanet ORPHA178819 (Hs)
Pharos P29371 (Hs)
RefSeq Nucleotide NM_001059 (Hs), NM_021382 (Mm), NM_017053 (Rn)
RefSeq Protein NP_001050 (Hs), NP_067357 (Mm), NP_058749 (Rn)
UniProtKB P29371 (Hs), P47937 (Mm), P16177 (Rn)
Wikipedia TACR3 (Hs)
Natural/Endogenous Ligands Click here for help
hemokinin 1 {Sp: Mouse}
neurokinin A {Sp: Human, Mouse, Rat}
neurokinin B {Sp: Human, Mouse, Rat, Pig}
substance P {Sp: Human, Mouse, Rat}
Comments: Neurokinin B is the highest potency endogenous agonist
Potency order of endogenous ligands (Human)
neurokinin B (TAC3, Q9UHF0) > neurokinin A (TAC1, P20366) > substance P (TAC1, P20366)

Download all structure-activity data for this target as a CSV file go icon to follow link

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
senktide Peptide Rn Full agonist 7.9 – 9.1 pKd 11,57
⤷ pKd 7.9 – 9.1 (Kd 1.2x10-8 – 9x10-10 M) [11,57]
[3H]senktide Peptide Ligand is labelled Ligand is radioactive Cp Full agonist 8.1 – 8.7 pKd 44
⤷ pKd 8.1 – 8.7 (Kd 8.52x10-9 – 2.21x10-9 M) [44]
hemokinin 1 {Sp: Mouse} Peptide Ligand is endogenous in the given species Mm Full agonist 9.2 – 9.3 pKi 83
⤷ pKi 9.2 – 9.3 [83]
[Phe(Me)7]neurokinin B Peptide Mm Full agonist 9.2 pKi 83
⤷ pKi 9.2 [83]
[Phe(Me)7]neurokinin B Peptide Click here for species-specific activity table Hs Full agonist 8.7 – 9.6 pKi 83,85
⤷ pKi 8.7 – 9.6 [83,85]
hemokinin 1 {Sp: Mouse} Peptide Click here for species-specific activity table Hs Full agonist 8.6 – 9.1 pKi 83
⤷ pKi 8.6 – 9.1 [83]
neurokinin B {Sp: Human, Mouse, Rat, Pig} Peptide Ligand is endogenous in the given species Mm Full agonist 8.6 – 8.7 pKi 83
⤷ pKi 8.6 – 8.7 [83]
neurokinin B {Sp: Human, Mouse, Rat, Pig} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Hs Full agonist 7.7 – 9.2 pKi 83,85
⤷ pKi 7.7 – 9.2 [83,85]
senktide Peptide Hs Full agonist 7.1 – 8.6 pKi 83,85,102
⤷ pKi 7.1 – 8.6 [83,85,102]
senktide Peptide Mm Full agonist 7.6 – 8.0 pKi 83
⤷ pKi 7.6 – 8.0 [83]
neurokinin A {Sp: Human, Mouse, Rat} Peptide Ligand is endogenous in the given species Mm Full agonist 6.1 pKi 83
⤷ pKi 6.1 [83]
neurokinin A {Sp: Human, Mouse, Rat} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Hs Full agonist 5.5 – 6.3 pKi 83,85
⤷ pKi 5.5 – 6.3 [83,85]
substance P {Sp: Human, Mouse, Rat} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Hs Full agonist 5.0 – 6.0 pKi 83,85
⤷ pKi 5.0 – 6.0 [83,85]
substance P {Sp: Human, Mouse, Rat} Peptide Ligand is endogenous in the given species Mm Full agonist 5.3 pKi 83
⤷ pKi 5.3 [83]
senktide Peptide Cp Agonist 9.3 pEC50 108
⤷ pEC50 9.3 (EC50 5x10-10 M) [108]
[Phe(Me)7]neurokinin B Peptide Click here for species-specific activity table Hs Full agonist 8.9 pEC50 15,24
⤷ pEC50 8.9 (EC50 1.3x10-9 M) [15,24]
neurokinin B {Sp: Human, Mouse, Rat, Pig} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Hs Full agonist 8.4 pEC50 11,24
⤷ pEC50 8.4 (EC50 4x10-9 M) [11,24]
senktide Peptide Rn Full agonist 7.9 – 8.8 pEC50 57
⤷ pEC50 7.9 – 8.8 (EC50 1.2x10-8 – 1.5x10-9 M) [57]
neurokinin A {Sp: Human, Mouse, Rat} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Hs Full agonist 7.4 pEC50 11
⤷ pEC50 7.4 (EC50 4x10-8 M) [11]
kassinin Peptide Click here for species-specific activity table Hs Full agonist 6.7 – 7.0 pIC50 102
⤷ pIC50 6.7 – 7.0 [102]
[Pro7]neurokinin B Peptide Hs Full agonist 6.4 – 6.6 pIC50 102
⤷ pIC50 6.4 – 6.6 [102]
eledoisin Peptide Click here for species-specific activity table Hs Full agonist 6.2 – 6.6 pIC50 11,102
⤷ pIC50 6.2 – 6.6 (IC50 5.894x10-7 – 2.642x10-7 M) [11,102]
[125I][MePhe7]NKB Peptide Ligand is labelled Ligand is radioactive Hs Full agonist - -
⤷
View species-specific agonist tables
Agonist Comments
Affinity data for guinea pig tachykinin receptors has been included as this species more closely mimics human tachykinin receptor expression pattern, gene sequence, and receptor function than do the rat or mouse.
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
[Trp7, β-Ala8] neurokinin A-(4-10) Peptide Rn Antagonist 7.5 pA2 24
⤷ pA2 7.5 [24]
[3H]osanetant Small molecule or natural product Ligand is labelled Ligand is radioactive Hs Antagonist 9.9 pKd
⤷ pKd 9.9 (Kd 1.3x10-10 M)
osanetant Small molecule or natural product Cp Antagonist 10.0 pKi 28
⤷ pKi 10.0 (Ki 1.1x10-10 M) [28]
SSR 146977 Small molecule or natural product Hs Antagonist 9.6 pKi 29
⤷ pKi 9.6 [29]
SCH 206272 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 9.5 pKi 2
⤷ pKi 9.5 [2]
osanetant Small molecule or natural product Click here for species-specific activity table Hs Antagonist 8.4 – 9.7 pKi 2,6,15,28,53,73,83,85,102
⤷ pKi 8.4 – 9.7 [2,6,15,28,53,73,83,85,102]
GSK 256471 Small molecule or natural product Hs Antagonist 9.0 pKi 91
⤷ pKi 9.0 [91]
SB 235375 Small molecule or natural product Hs Antagonist 8.7 pKi 48
⤷ pKi 8.7 (Ki 2.2x10-9 M) [48]
pavinetant Small molecule or natural product Primary target of this compound Hs Antagonist 8.7 pKi 3
⤷ pKi 8.7 (Ki 2x10-9 M) [3]
FK 224 Peptide Click here for species-specific activity table Hs Antagonist 8.2 – 8.4 pKi 68
⤷ pKi 8.2 – 8.4 [68]
talnetant Small molecule or natural product Click here for species-specific activity table Hs Antagonist 7.4 – 9.0 pKi 7,39,83,85
⤷ pKi 7.4 – 9.0 [7,39,83,85]
GSK 172981 Small molecule or natural product Cp Antagonist 8.1 pKi 23
⤷ pKi 8.1 (Ki 7.8x10-9 M) [23]
GSK 256471 Small molecule or natural product Cp Antagonist 8.1 pKi 23
⤷ pKi 8.1 (Ki 8.4x10-9 M) [23]
GSK 172981 Small molecule or natural product Hs Antagonist 8.0 pKi 91
⤷ pKi 8.0 [91]
PD157672 Small molecule or natural product Hs Antagonist 7.8 – 8.0 pKi 15
⤷ pKi 7.8 – 8.0 [15]
SB 218795 Small molecule or natural product Hs Antagonist 7.8 – 8.0 pKi 39
⤷ pKi 7.8 – 8.0 (Ki 1.6x10-8 – 1.06x10-8 M) [39]
fezolinetant Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 7.6 pKi 49
⤷ pKi 7.6 (Ki 2.51x10-8 M) [49]
Description: Binding to recombinant human NK3R expressed in CHO cells.
SB 222200 Small molecule or natural product Hs Antagonist 6.6 – 8.4 pKi 83-84
⤷ pKi 6.6 – 8.4 [83-84]
PD 154740 Small molecule or natural product Hs Antagonist 7.4 pKi 15
⤷ pKi 7.4 (Ki 4x10-8 M) [15]
talnetant Small molecule or natural product Rn Antagonist 7.3 – 7.4 pKi 83
⤷ pKi 7.3 – 7.4 [83]
GR138676 Peptide Hs Antagonist 6.0 pKi 92
⤷ pKi 6.0 [92]
saredutant Small molecule or natural product Click here for species-specific activity table Hs Antagonist 5.7 – 6.2 pKi 2,85
⤷ pKi 5.7 – 6.2 [2,85]
N',2-diphenylquinoline-4-carbohydrazide 8m Small molecule or natural product Hs Antagonist 8.4 pIC50 27
⤷ pIC50 8.4 [27]
N′,2-diphenylquinoline-4-carbohydrazide Small molecule or natural product Hs Antagonist 7.9 – 8.4 pIC50 26
⤷ pIC50 7.9 – 8.4 [26]
PD 161182 Small molecule or natural product Hs Antagonist 8.1 pIC50 8
⤷ pIC50 8.1 (IC50 7x10-9 M) [8]
osanetant Small molecule or natural product Click here for species-specific activity table Hs Antagonist 7.9 – 8.0 pIC50 15
⤷ pIC50 7.9 – 8.0 (IC50 1.2x10-8 – 1x10-8 M) [15]
PD157672 Small molecule or natural product Hs Antagonist 7.8 – 7.9 pIC50 8,102
⤷ pIC50 7.8 – 7.9 (IC50 1.6x10-8 – 1.21x10-8 M) [8,102]
SB 222200 Small molecule or natural product Hs Antagonist 7.7 pIC50 84
⤷ pIC50 7.7 (IC50 1.84x10-8 M) [84]
saredutant Small molecule or natural product Click here for species-specific activity table Hs Antagonist 6.5 pIC50 16
⤷ pIC50 6.5 (IC50 3.5x10-7 M) [16]
PD 154740 Small molecule or natural product Hs Antagonist 6.2 – 6.2 pIC50 15
⤷ pIC50 6.2 – 6.2 (IC50 6.8x10-7 – 5.8x10-7 M) [15]
View species-specific antagonist tables
Antagonist Comments
Affinity data for guinea pig tachykinin receptors has been included as this species more closely mimics human tachykinin receptor expression pattern, gene sequence, and receptor function than do the rat or mouse.

SR48968 is an inhibitor in guinea pigs but not in rats, where it is specific for NK2 receptor. Two amino acids in the first and second transmembrane domains are responsible for differences in species specificity. In addition, SR48968 is a non-selective antagonist in that it can antagonize the NK1 and NK2 receptors in humans and guinea pigs as well. SR 142801 appears to have an effect on all tachykinin receptors to varying degrees with the concentration for inhibition greatly exceeding that of inhibitors specific to these receptors. SR 142801 is specific to the NK3 receptor as the Ki is less than 1nM. PD154740 and PD157672 display a similiar species specificity. PD157672 and PD161182 are peptide derived antagonists.
Primary Transduction Mechanisms Click here for help
Transducer Effector/Response
Gq/G11 family Phospholipase C stimulation
References:  99
Tissue Distribution Click here for help
Total human embryo.
Species:  Human
Technique:  RT-PCR.
References:  11
Hippocampus.
Species:  Human
Technique:  RT-PCR.
References:  11
Frontal cortex, temporal cortex, parietal cortex.
Species:  Human
Technique:  RT-PCR.
References:  11
Locus niger.
Species:  Human
Technique:  RT-PCR.
References:  11
Hypothalamus.
Species:  Human
Technique:  RT-PCR.
References:  11
Brain; glia limitans at the pial surface (astrocytes and beaded fibres), all cortical layers, white matter (astrocytes and beaded fibres, particularly surrounding blood vessels).
Species:  Human
Technique:  Immunohistochemistry.
References:  104
Kidney.
Species:  Human
Technique:  RT-PCR.
References:  11
Sigmoid colon: gastro myenteric and submucosal plexus.
Species:  Human
Technique:  Immunohistochemistry.
References:  22
Prefrontal and visual cortex; beaded fibres and cells with astrocyte-like morphology in the superficial cortical layers and white matter, dots in the neuropil and on pyramidal (layers III/V) and non-pyramidal (layers V/VI) cells.
Species:  Human
Technique:  Immunohistochemistry.
References:  103
Striatum.
Species:  Human
Technique:  RT-PCR.
References:  11
Placenta.
Species:  Human
Technique:  RT-PCR.
References:  11
Smooth muscle cells of the esophagus, stomach, and intestines. Submucousal nerve plexus or myenteric nerve plexus of the gastrointestinal tract except for the esophagus, stomach and rectum.
Species:  Mouse
Technique:  Unspecified
References:  42,107
Striatum; nitric oxide synthase/preprosomatostatin containing GABAergic interneurones.
Species:  Mouse
Technique:  in situ hybridization.
References:  78
Mouse ileum; neurons and interstitial cells of Cajal at the deep muscular plexus, inner portion of the circular muscle layer.
Species:  Mouse
Technique:  Immunohistochemistry.
References:  106
Medial habenula nucleus.
Species:  Rat
Technique:  Extracellular recording.
References:  71
Portal vein.
Species:  Rat
Technique:  Organ bath physiological measurement.
References:  65
Mid-cortical layers.
Species:  Rat
Technique:  Radioligand binding.
References:  21
Supraoptic nucleus.
Species:  Rat
Technique:  Radioligand binding.
References:  21
Zona incerta.
Species:  Rat
Technique:  Radioligand binding.
References:  21
Amygdala.
Species:  Rat
Technique:  Radioligand binding.
References:  21
Substantia nigra pars compacta.
Species:  Rat
Technique:  Radioligand binding.
References:  21
Ventral tegumental area.
Species:  Rat
Technique:  Radioligand binding.
References:  21
Hippocampus.
Species:  Rat
Technique:  Radioligand binding.
References:  21
Hypothalamus.
Species:  Rat
Technique:  Radioligand binding.
References:  21
Spinal cord; lamina II (dendritic spines inside glomeruli, preterminal axons and axon terminals) and lamina X.
Species:  Rat
Technique:  immunocytochemistry.
References:  110
Dorsal vagal complex.
Species:  Rat
Technique:  immunocytochemistry.
References:  12
Kidney.
Species:  Rat
Technique:  Autoradiography.
References:  14
Pancreatic acini.
Species:  Rat
Technique:  immunocytochemistry.
References:  9
Mid-cortical layer of cortex: cingulate cortex > frontoparietal cortex > retrosplenial cortex.

Basal ganglia: caudate putamen, anterior.

Zona incerta.

Hypothalamus: paraventricular nucleus > supraoptic nucleus > dorsomedial hypothalamus nucleus > supramammillary nucleus.

Medial habenula.

Amygdala: basolateral amygdaloid nucleus > basomedial amygdaloid nucleus > amygdalohippocampal area.

Hippocampus: CA3, vetral.

Midbrain: ventral tagmental area > interpeduncular nucleus > substantia nigra, pars compacta > median raphe nucleus > superior colliculus.

Pons: sphenoid nucleus > posterodorsal tagmental nucleus.
Species:  Rat
Technique:  Autoradiography.
References:  56,97
Nucleus tractus solitarius and dorsal vagal motor neurone regions of the brainstem.
Species:  Rat
Technique:  Immunohistochemistry.
References:  66
Cortex, amygdala, hippocampus, medial habenula, zona incerta, paraventricular and supraoptic nuclei of the hypothalamus, substantia nigra, ventral tegmental area, interpeduncular nucleus, raphe nuclei, dorsal tegmental nucleus, nucleus of the solitary tract, olfactory bulb, dentate gyrus and subiculum, medial septum, diagonal band of Broca, ventral pallidum, globus pallidus, bed nucleus of the stria terminalis, arcuate, premammillary and mammillary nuclei, dorsal and lateral regions of the posterior hypothalamus, central gray, cerebellum, parabrachial nuclei, nucleus of the spinal trigeminal tract, dorsal horn of the spinal cord, retina.
Species:  Rat
Technique:  in situ hybridization.
References:  89
Gustatory centers; rostral nucleus of the solitary tract, caudal half of dorsocentral zone, external medial subnucleus.
Species:  Rat
Technique:  Immunohistochemistry.
References:  47
Blood vessels in oral tissues.
Species:  Rat
Technique:  Immunohistochemistry.
References:  37
Brainstem auditory nuclei; cochlear nucleus, lateral superior olive, the medial nucleus of the trapezoid body, and inferior colliculus.
Species:  Rat
Technique:  Immunohistochemistry.
References:  46
Duodemum, ileum, colon, rectum; myenteric plexus > submucous plexus.
Species:  Rat
Technique:  Immunohistochemistry.
References:  63
Lateral hypothalamus and the zona incerta; melanin-concentrating hormone (MCH) neurons.
Species:  Rat
Technique:  Immunocytochemistry, in situ hybridization.
References:  43
Uterus.
Species:  Rat
Technique:  Autoradiography.
References:  5
Paraventricular nucleus (magnocellular part) and hypothalamus (supraoptic nucleus).
Species:  Rat
Technique:  Autoradiography, in situ hybridization.
References:  25
Mysenteric plexus of the ileum.
Species:  Guinea pig
Technique:  Radioligand binding.
References:  44
Tissue Distribution Comments
The rat portal vein is the preferred tissue for the assay of NK3 receptors as guinea pig ileum expresses NK1 receptors limiting its use in contractile studies designed to investigate the pharmacology of the NK3 receptor.
Expression Datasets Click here for help

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays Click here for help
Measurement of intracellular Ca2+ in CHO cells transfected with the human NK3 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Increase in intracellular Ca2+.
References:  76
Physiological Functions Click here for help
Modulation of gastric secretion.
Species:  Rat
Tissue:  In vivo.
References:  51
Involved in interleukin-1β-induced NGF release and airway hyperresponsiveness.
Species:  Human
Tissue:  Isolated human bronchi.
References:  70
Stimulation of amylase secretion in isolated rat pancreatic acini.
Species:  Rat
Tissue:  Pancreatic acini.
References:  62
Inhibition of nociception associated with intestinal distension.
Species:  Rat
Tissue:  Intestine.
References:  31
Enhancement of substance P release from capsaicin-sensitive spinal cord afferent terminals.
Species:  Rat
Tissue:  In vivo.
References:  86
Involvement in intestinal and somatic nociceptive responses and intestinal motility in anaesthetized rats.
Species:  Rat
Tissue:  In vivo.
References:  87
A subpopulation of dopamine-sensitive neurones in the substantia nigra zona compacta are potently excited by an NK3 receptor agonist.
Species:  Rat
Tissue:  Substantia nigra zona compacta.
References:  55
Locomotion, rearing and sniffing are observed following infusion of an NK3 agonist into the substantia nigra pars compacta, and to a lesser extent in the ventral tegmental area. Yawning, chewing mouth movements and wet dog shakes are seen following infusion of an NK3 agonist into the ventral tegmental area.
Species:  Rat
Tissue:  In vivo.
References:  98
Following intracisternal administration NK3 agonists cause behaviour typically associated with serotonergic stimulation, including head twitches, reciprocal forepaw treading and hindlimb splaying.
Species:  Mouse
Tissue:  In vivo.
References:  96
Intraventricular injections of an NK3 agonist suppress the ingestion of hypertonic NaCl aqueous solution.
Species:  Rat
Tissue:  In vivo.
References:  32,34-36,77,90
Mediation of the baroreflex function.
Species:  Rat
Tissue:  In vivo.
References:  33
Alterations in luteinizing hormone secretion.
Species:  Rat
Tissue:  In vivo.
References:  82
Centrally administered NK3 antagonists cause a sustained and dose-dependent reduction of blood pressure in hypertensive rats.
Species:  Rat
Tissue:  In vivo.
References:  60
Modulation of inflammation in experimentally-induced colitis in rats.
Species:  Rat
Tissue:  In vivo.
References:  52
Endogenous NK3 activity in the substantia nigra maintains high blood pressure in spontaneously hypertensive rats.
Species:  Rat
Tissue:  In vivo.
References:  59
NK3 receptor activation induces neuronal bursting.
Species:  Rat
Tissue:  Isolated neonatal spinal cord.
References:  45,64
Antidepressant-type effects; in forced swim tests in mouse lines selectively bred for divergent magnitudes of stress-induced analgesia, NK3 activation reduced immobility more in opioid receptor-dense high analgesia lines than in unselected mice, but was ineffective in the opioid receptor-deficient low analgesia line.
Species:  Mouse
Tissue:  In vivo.
References:  74
NK3 blocking depresses windup of spinal neurons.
Species:  Rat
Tissue:  Neonatal rat spinal.
References:  4
Modulation of thermal hyperalgesia in induced monoarthritic rats.
Species:  Rat
Tissue:  In vivo.
References:  109
Activation of central tachykinin NK3 receptors inhibits colonic propolsion.
Species:  Rat
Tissue:  In vivo.
References:  10
Modulation of mean arterial pressure, heart rate and motor behaviour (face washing, sniffing, wet dog shakes).
Species:  Rat
Tissue:  In vivo.
References:  13,101
Modulation of NO-dependent vasodilatation.
Species:  Rat
Tissue:  Isolated mesenteric arteries.
References:  67
In a murine model of allergic asthma, blocking of NK3 causes caused a significant decrease in the number of neutrophils and eosinophils.
Species:  Mouse
Tissue:  In vivo.
References:  72
Modulation of gamma-aminobutyric acid (GABA) release.
Species:  Mouse
Tissue:  Striatal brain slices.
References:  78
Modulation of experimental anxiety.
Species:  Mouse
Tissue:  In vivo.
References:  79
NK3 blocking decreases the amplitude and square of stimulated compound action potentials.
Species:  Rat
Tissue:  Caudal mesenteric ganglion.
References:  75
Modulation of colonic distention-induced reflex rhythmic contractions; activation of NO-dependent and NO-independent inhibitory neurotransmission.
Species:  Rat
Tissue:  Colon.
References:  58
Regulation of giant contraction in isolated colon.
Species:  Rat
Tissue:  Isolated colon.
References:  41
Modulation of behavioural responses to noxious colo-rectal distension.
Species:  Rat
Tissue:  In vivo.
References:  38,54,81,87
Rectal distension-induced colonic net water hypersecretion is blocked by NK3 antagonists when injected intracerebroventricularly.
Species:  Rat
Tissue:  In vivo.
References:  30
Intracerebroventricular injection of NK3 receptor agonists inhibits alcohol intake in genetically selected alcohol-preferring rats.
Species:  Rat
Tissue:  In vivo.
References:  17-19
Analgesic effects are induced by NK3 receptor agonists administered to either the ventral tegmental area or nucleus accumbens septi.
Species:  Rat
Tissue:  In vivo.
References:  1
Activation of NK3 receptors in the hypothalamic paraventricular nucleus elicits antidiuretic actions.
Species:  Rat
Tissue:  In vivo.
References:  25,80
Modulation of pressor response.
Species:  Rat
Tissue:  In vivo.
References:  69,101
Modulation of vacoconstriction.
Species:  Rat
Tissue:  Arterial and venous mesenteric beds.
References:  20
Behavioural manifestations of 5-hydroxytryptaminergic stimulation (including head twitches, forepaw treading, flat body posture, hindlimb splaying and Straub tail).
Species:  Mouse
Tissue:  In vivo.
References:  95
Activation stimulatess yawning, chewing mouth movements and sexual arousal.
Species:  Rat
Tissue:  In vivo.
References:  94
Control of presynaptic dopamine release.
Species:  Rat
Tissue:  In vivo.
References:  40,105
Stimulation of oral movements.
Species:  Rat
Tissue:  In vivo.
References:  61
Induction of grooming.
Species:  Rat
Tissue:  In vivo.
References:  93
Phenotypes, Alleles and Disease Models Click here for help Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Tacr3tm1Jasi Tacr3tm1Jasi/Tacr3tm1Jasi
involves: 129P2/OlaHsd * C57BL/6		 MGI:892968  MP:0002798 abnormal active avoidance behavior PMID: 17558564 
Tacr3tm1Jasi Tacr3tm1Jasi/Tacr3tm1Jasi
involves: 129P2/OlaHsd * C57BL/6		 MGI:892968  MP:0001463 abnormal spatial learning PMID: 17558564 
Tacr3tm1Jasi Tacr3tm1Jasi/Tacr3tm1Jasi
involves: 129P2/OlaHsd * C57BL/6		 MGI:892968  MP:0004000 impaired passive avoidance behavior PMID: 17558564 
Tacr3tm1Jasi Tacr3tm1Jasi/Tacr3tm1Jasi
involves: 129P2/OlaHsd * C57BL/6		 MGI:892968  MP:0001260 increased body weight PMID: 17558564 
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Hypogonadotropic hypogonadism 11 with or without anosmia; HH11
Synonyms: Kallmann syndrome [Orphanet: ORPHA478] [Disease Ontology: DOID:3614]
Normosmic congenital hypogonadotropic hypogonadism [Orphanet: ORPHA432]
Disease Ontology: DOID:3614
OMIM: 614840
Orphanet: ORPHA432, ORPHA478

References

Show »

1. Altier N, Stewart J. (1997) Tachykinin NK-1 and NK-3 selective agonists induce analgesia in the formalin test for tonic pain following intra-VTA or intra-accumbens microinfusions. Behav Brain Res, 89 (1-2): 151-65. [PMID:9475623]

2. Anthes JC, Chapman RW, Richard C, Eckel S, Corboz M, Hey JA, Fernandez X, Greenfeder S, McLeod R, Sehring S et al.. (2002) SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. Eur J Pharmacol, 450 (2): 191-202. [PMID:12206858]

3. AstraZeneca. AZD2624. Accessed on 11/09/2014. Modified on 11/09/2014. astrazeneca.com, http://openinnovation.astrazeneca.com/what-we-offer/compound/azd2624/

4. Barbieri M, Nistri A. (2001) Depression of windup of spinal neurons in the neonatal rat spinal cord in vitro by an NK3 tachykinin receptor antagonist. J Neurophysiol, 85: 1502-1511. [PMID:11287474]

5. Barr AJ, Watson SP, Bernal AL, Nimmo AJ. (1991) The presence of NK3 tachykinin receptors on rat uterus. Eur J Pharmacol, 203 (2): 287-90. [PMID:1724757]

6. Beaujouan JC, Saffroy M, Torrens Y, Glowinski J. (1997) Potency and selectivity of the tachykinin NK3 receptor antagonist SR 142801. Eur J Pharmacol, 319 (2-3): 307-16. [PMID:9042606]

7. Bennacef I, Tymciu S, Dhilly M, Lasne MC, Debruyne D, Perrio C, Barré L. (2004) Synthesis and biological evaluation of novel fluoro and iodo quinoline carboxamides as potential ligands of NK-3 receptors for in vivo imaging studies. Bioorg Med Chem, 12 (16): 4533-41. [PMID:15265501]

8. Boden P, Eden JM, Hodgson J, Horwell DC, Hughes J, McKnight AT, Lewthwaite RA, Pritchard MC, Raphy J, Meecham K et al.. (1996) Use of a dipeptide chemical library in the development of non-peptide tachykinin NK3 receptor selective antagonists. J Med Chem, 39 (8): 1664-75. [PMID:8648606]

9. Broccardo M, Ciotti MT, Linari G, Agostini S, Petrella C, Amadoro G, Severini C, Improta G. (2005) Immunocytochemical distribution of NK-1 and NK-3 tachykinin receptors in isolated pancreatic acini of guinea pigs and rats. Peptides, 26 (11): 2351-4. [PMID:15970359]

10. Broccardo M, Improta G, Tabacco A. (1999) Central tachykinin NK3 receptors in the inhibitory action on the rat colonic propulsion of a new tachykinin, PG-KII. Eur J Pharmacol, 376 (1-2): 67-71. [PMID:10440091]

11. Buell G, Schulz MF, Arkinstall SJ, Maury K, Missotten M, Adami N, Talabot F, Kawashima E. (1992) Molecular characterisation, expression and localisation of human neurokinin-3 receptor. FEBS Lett, 299 (1): 90-5. [PMID:1312036]

12. Carpentier C, Baude A. (1996) Immunocytochemical localisation of NK3 receptors in the dorsal vagal complex of rat. Brain Res, 734 (1-2): 327-31. [PMID:8896842]

13. Cellier E, Barbot L, Regoli D, Couture R. (1997) Cardiovascular and behavioural effects of intracerebroventricularly administered tachykinin NK3 receptor antagonists in the conscious rat. Br J Pharmacol, 122 (4): 643-54. [PMID:9375960]

14. Chen Y, Hoover DB. (1995) Autoradiographic localization of NK1 and NK3 tachykinin receptors in rat kidney. Peptides, 16 (4): 673-81. [PMID:7479302]

15. Chung FZ, Wu LH, Tian Y, Vartanian MA, Lee H, Bikker J, Humblet C, Pritchard MC, Raphy J, Suman-Chauhan N. (1995) Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor. Mol Pharmacol, 48 (4): 711-6. [PMID:7476898]

16. Chung FZ, Wu LH, Vartanian MA, Watling KJ, Guard S, Woodruff GN, Oxender DL. (1994) The non-peptide tachykinin NK2 receptor antagonist SR 48968 interacts with human, but not rat, cloned tachykinin NK3 receptors. Biochem Biophys Res Commun, 198 (3): 967-72. [PMID:8117304]

17. Ciccocioppo R, Panocka I, Polidori C, De Caro G, Regoli D, Massi M. (1997) Stimulation of tachykinin NK-3 receptors in the nucleus basalis magnocellularis reduces alcohol intake in rats. Peptides, 18 (9): 1349-55. [PMID:9392836]

18. Ciccocioppo R, Panocka I, Polidori C, Froldi R, Angeletti S, Massi M. (1998) Mechanism of action for reduction of ethanol intake in rats by the tachykinin NK-3 receptor agonist aminosenktide. Pharmacol Biochem Behav, 61 (4): 459-64. [PMID:9802842]

19. Ciccocioppo R, Panocka I, Pompei P, De Caro G, Massi M. (1994) Selective agonists at NK3 tachykinin receptors inhibit alcohol intake in Sardinian alcohol-preferring rats. Brain Res Bull, 33 (1): 71-7. [PMID:7506113]

20. D'Orléans-Juste P, Claing A, Télémaque S, Warner TD, Regoli D. (1991) Neurokinins produce selective venoconstriction via NK-3 receptors in the rat mesenteric vascular bed. Eur J Pharmacol, 204 (3): 329-34. [PMID:1723050]

21. Dam TV, Escher E, Quirion R. (1990) Visualization of neurokinin-3 receptor sites in rat brain using the highly selective ligand [3H]senktide. Brain Res, 506 (1): 175-9. [PMID:1689199]

22. Dass NB, Bassil A, Morgan M, Sanger GJ. (2002) Localisation and distribution of functional neurokinin-3 (NK3) receptors in human gastrointestinal tract. Gastroenterology, 122: (suppl 1)-.

23. Dawson LA, Langmead CJ, Dada A, Watson JM, Wu Z, de la Flor R, Jones GA, Cluderay JE, Southam E, Murkitt GS et al.. (2010) In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. Eur J Pharmacol, 627 (1-3): 106-14. [PMID:19879867]

24. Drapeau G, Rouissi N, Nantel F, Rhaleb NE, Tousignant C, Regoli D. (1990) Antagonists for the neurokinin NK-3 receptor evaluated in selective receptor systems. Regul Pept, 31 (2): 125-35. [PMID:2176308]

25. Eguchi T, Takano Y, Hatae T, Saito R, Nakayama Y, Shigeyoshi Y, Okamura H, Krause JE, Kamiya H. (1996) Antidiuretic action of tachykinin NK-3 receptor in the rat paraventricular nucleus. Brain Res, 743 (1-2): 49-55. [PMID:9017229]

26. Elliott JM, Carling RW, Chambers M, Chicchi GG, Hutson PH, Jones AB, MacLeod A, Marwood R, Meneses-Lorente G, Mezzogori E et al.. (2006) N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists. Bioorg Med Chem Lett, 16 (22): 5748-51. [PMID:16950620]

27. Elliott JM, Carling RW, Chicchi GG, Crawforth J, Hutson PH, Jones AB, Kelly S, Marwood R, Meneses-Lorente G, Mezzogori E et al.. (2006) N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II. Bioorg Med Chem Lett, 16 (22): 5752-6. [PMID:16950617]

28. Emonds-Alt X, Bichon D, Ducoux JP, Heaulme M, Miloux B, Poncelet M, Proietto V, Van Broeck D, Vilain P, Neliat G. (1995) SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sci, 56 (1): PL27-32. [PMID:7830490]

29. Emonds-Alt X, Proietto V, Steinberg R, Advenier C, Daoui S, Naline E, Gueudet C, Michaud JC, Oury-Donat F, Poncelet M et al.. (2002) Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. Can J Physiol Pharmacol, 80 (5): 482-8. [PMID:12056557]

30. Eutamene H, Theodorou V, Fioramonti J, Bueno L. (1997) Rectal distention-induced colonic net water secretion in rats involves tachykinins, capsaicin sensory, and vagus nerves. Gastroenterology, 112 (5): 1595-602. [PMID:9136838]

31. Fioramonti J, Gaultier E, Toulouse M, Sanger GJ, Bueno L. (2003) Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action. Neurogastroenterol Motil, 15 (4): 363-9. [PMID:12846724]

32. Flynn FW. (2000) Intraventricular injection of tachykinin NK3 receptor agonists suppresses the ingestion of NaCl-associated tastes. Behav Neurosci, 114 (6): 1223-8. [PMID:11142654]

33. Flynn FW. (2005) Intraventricular injections of tachykinin NK3 receptor agonist reduce the gain of the baroreflex in unrestrained rats. Exp Neurol, 193 (1): 118-24. [PMID:15817270]

34. Flynn FW. (2006) Intraventricular injections of tachykinin NK3 receptor agonists suppress the intake of "salty" tastes by sodium deficient rats. Behav Brain Res, 166 (1): 1-8. [PMID:16154648]

35. Flynn FW, Smith ME. (1998) Lateral ventricular injections of the NK3 agonist senktide affect salt taste-elicited responses. Peptides, 19 (2): 319-24. [PMID:9493864]

36. Flynn FW, Smith ME, Bieber SL. (1999) Differential effects of intraventricular injections of tachykinin NK1 and NK3 receptor agonists on normal and sham drinking of NaCl by sodium-deficient rats. Behav Neurosci, 113 (4): 776-86. [PMID:10495085]

37. Fristad I, Vandevska-Radunovic V, Fjeld K, Wimalawansa SJ, Hals Kvinnsland I. (2003) NK1, NK2, NK3 and CGRP1 receptors identified in rat oral soft tissues, and in bone and dental hard tissue cells. Cell Tissue Res, 311 (3): 383-91. [PMID:12658446]

38. Gaudreau GA, Plourde V. (2003) Role of tachykinin NK1, NK2 and NK3 receptors in the modulation of visceral hypersensitivity in the rat. Neurosci Lett, 351 (2): 59-62. [PMID:14583381]

39. Giardina GA, Sarau HM, Farina C, Medhurst AD, Grugni M, Foley JJ, Raveglia LF, Schmidt DB, Rigolio R, Vassallo M et al.. (1996) 2-Phenyl-4-quinolinecarboxamides: a novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptor. J Med Chem, 39 (12): 2281-4. [PMID:8691422]

40. Glowinski J, Kemel ML, Desban M, Gauchy C, Lavielle S, Chassaing G, Beaujouan JC, Tremblay L. (1993) Distinct presynaptic control of dopamine release in striosomal- and matrix-enriched areas of the rat striatum by selective agonists of NK1, NK2 and NK3 tachykinin receptors. Regul Pept, 46 (1-2): 124-8. [PMID:7692480]

41. Gonzalez A, Sarna SK. (2001) Neural regulation of in vitro giant contractions in the rat colon. Am J Physiol Gastrointest Liver Physiol, 281 (1): G275-82. [PMID:11408281]

42. Grady EF, Baluk P, Böhm S, Gamp PD, Wong H, Payan DG, Ansel J, Portbury AL, Furness JB, McDonald DM et al.. (1996) Characterization of antisera specific to NK1, NK2, and NK3 neurokinin receptors and their utilization to localize receptors in the rat gastrointestinal tract. J Neurosci, 16 (21): 6975-86. [PMID:8824334]

43. Griffond B, Ciofi P, Bayer L, Jacquemard C, Fellmann D. (1997) Immunocytochemical detection of the neurokinin B receptor (NK3) on melanin-concentrating hormone (MCH) neurons in rat brain. J Chem Neuroanat, 12 (3): 183-9. [PMID:9141650]

44. Guard S, Watson SP, Maggio JE, Too HP, Watling KJ. (1990) Pharmacological analysis of [3H]-senktide binding to NK3 tachykinin receptors in guinea-pig ileum longitudinal muscle-myenteric plexus and cerebral cortex membranes. Br J Pharmacol, 99 (4): 767-73. [PMID:1694464]

45. Guo JZ, Yoshioka K, Otsuka M. (1998) Effects of a tachykinin NK3 receptor antagonist, SR 142801, studied in isolated neonatal rat spinal cord. Neuropeptides, 32 (6): 537-42. [PMID:9920451]

46. Hafidi A, Beurg M, Bouleau Y, Dulon D. (2002) Comparative distribution of NK1, NK2, and NK3 receptors in the rat brainstem auditory nuclei. Brain Res, 947 (2): 299-306. [PMID:12176174]

47. Harrison TA, Hoover DB, King MS. (2004) Distinct regional distributions of NK1 and NK3 neurokinin receptor immunoreactivity in rat brainstem gustatory centers. Brain Res Bull, 63 (1): 7-17. [PMID:15121234]

48. Hay DW, Giardina GA, Griswold DE, Underwood DC, Kotzer CJ, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ et al.. (2002) Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs. J Pharmacol Exp Ther, 300 (1): 314-23. [PMID:11752131]

49. Hoveyda HR, Fraser GL, Dutheuil G, El Bousmaqui M, Korac J, Lenoir F, Lapin A, Noël S. (2015) Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II). ACS Med Chem Lett, 6 (7): 736-40. [PMID:26191358]

50. Huang RR, Cheung AH, Mazina KE, Strader CD, Fong TM. (1992) cDNA sequence and heterologous expression of the human neurokinin-3 receptor. Biochem Biophys Res Commun, 184 (2): 966-72. [PMID:1374246]

51. Improta G, Broccardo M. (1991) Inhibitory role on gastric secretion of a central NK-3 tachykinin receptor agonist, senktide. Peptides, 12 (6): 1433-4. [PMID:1726124]

52. Improta G, Carpino F, Petrozza V, Guglietta A, Tabacco A, Broccardo M. (2003) Central effects of selective NK1 and NK3 tachykinin receptor agonists on two models of experimentally-induced colitis in rats. Peptides, 24 (6): 903-11. [PMID:12948843]

53. Kamali F. (2001) Osanetant Sanofi-Synthélabo. Curr Opin Investig Drugs, 2 (7): 950-6. [PMID:11757797]

54. Kamp EH, Beck DR, Gebhart GF. (2001) Combinations of neurokinin receptor antagonists reduce visceral hyperalgesia. J Pharmacol Exp Ther, 299 (1): 105-13. [PMID:11561069]

55. Keegan KD, Woodruff GN, Pinnock RD. (1992) The selective NK3 receptor agonist senktide excites a subpopulation of dopamine-sensitive neurones in the rat substantia nigra pars compacta in vitro. Br J Pharmacol, 105: 3-5. [PMID:1375857]

56. Langlois X, Wintmolders C, te Riele P, Leysen JE, Jurzak M. (2001) Detailed distribution of Neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study. Neuropharmacology, 40 (2): 242-53. [PMID:11114403]

57. Laufer R, Gilon C, Chorev M, Selinger Z. (1986) Characterization of a neurokinin B receptor site in rat brain using a highly selective radioligand. J Biol Chem, 261 (22): 10257-63. [PMID:2426259]

58. Lecci A, Giuliani S, Tramontana M, Meini S, De Giorgio R, Maggi CA. (1996) In vivo evidence for the involvement of tachykinin NK3 receptors in the hexamethonium-resistant inhibitory transmission in the rat colon. Naunyn Schmiedebergs Arch Pharmacol, 353 (6): 671-9. [PMID:8738300]

59. Lessard A, Campos MM, Neugebauer W, Couture R. (2003) Implication of nigral tachykinin NK3 receptors in the maintenance of hypertension in spontaneously hypertensive rats: a pharmacologic and autoradiographic study. Br J Pharmacol, 138 (4): 554-63. [PMID:12598409]

60. Lessard A, Laurin M, Yamaguchi N, Couture R. (2004) Central anti-hypertensive effect of tachykinin NK3 receptor antagonists in rat. Eur J Pharmacol, 486 (1): 75-83. [PMID:14751411]

61. Liminga U, Johansson PE, Gunne L. (1991) Intranigral tachykinin NK3 receptor agonist elicits oral movements in rats. Pharmacol Biochem Behav, 38 (3): 617-20. [PMID:1712496]

62. Linari G, Improta G, Agostini S, Andreassi A, Broccardo M. (2004) Stimulatory effect of PG-KII, an NK3 tachykinin receptor agonist, on isolated pancreatic acini: species-related differences. Peptides, 25 (1): 45-51. [PMID:15003355]

63. Mann PT, Southwell BR, Ding YQ, Shigemoto R, Mizuno N, Furness JB. (1997) Localisation of neurokinin 3 (NK3) receptor immunoreactivity in the rat gastrointestinal tract. Cell Tissue Res, 289 (1): 1-9. [PMID:9182595]

64. Marchetti C, Nistri A. (2001) Neuronal bursting induced by NK3 receptor activation in the neonatal rat spinal cord in vitro. J Neurophysiol, 86 (6): 2939-50. [PMID:11731550]

65. Mastrangelo D, Mathison R, Huggel HJ, Dion S, D'Orléans-Juste P, Rhaleb NE, Drapeau G, Rovero P, Regoli D. (1987) The rat isolated portal vein: a preparation sensitive to neurokinins, particularly neurokinin B. Eur J Pharmacol, 134 (3): 321-6. [PMID:3471518]

66. Mileusnic D, Lee JM, Magnuson DJ, Hejna MJ, Krause JE, Lorens JB, Lorens SA. (1999) Neurokinin-3 receptor distribution in rat and human brain: an immunohistochemical study. Neuroscience, 89 (4): 1269-90. [PMID:10362314]

67. Mizuta A, Takano Y, Honda K, Saito R, Matsumoto T, Kamiya H. (1995) Nitric oxide is a mediator of tachykinin NK3 receptor-induced relaxation in rat mesenteric artery. Br J Pharmacol, 116 (7): 2919-22. [PMID:8680725]

68. Morimoto H, Murai M, Maeda Y, Yamaoka M, Nishikawa M, Kiyotoh S, Fujii T. (1992) FK 224, a novel cyclopeptide substance P antagonist with NK1 and NK2 receptor selectivity. J Pharmacol Exp Ther, 262 (1): 398-402. [PMID:1378096]

69. Nakayama Y, Takano Y, Saito R, Kamiya H. (1992) Central pressor actions of tachykinin NK-3 receptor in the paraventricular nucleus of the rat hypothalamus. Brain Res, 595 (2): 339-42. [PMID:1281741]

70. Naline E, Höglund CO, Vincent F, Emonds-Alt X, Lagente V, Advenier C, Frossard N. (2007) Role of tachykinin NK3 receptors in the release and effects of nerve growth factor in human isolated bronchi. Eur J Pharmacol, 560 (2-3): 206-11. [PMID:17306250]

71. Norris SK, Boden PR, Woodruff GN. (1993) Agonists selective for tachykinin NK1 and NK3 receptors excite subpopulations of neurons in the rat medial habenula nucleus in vitro. Eur J Pharmacol, 234 (2-3): 223-8. [PMID:7683268]

72. Nénan S, Germain N, Lagente V, Emonds-Alt X, Advenier C, Boichot E. (2001) Inhibition of inflammatory cell recruitment by the tachykinin NK(3)-receptor antagonist, SR 142801, in a murine model of asthma. Eur J Pharmacol, 421 (3): 201-5. [PMID:11516437]

73. Oury-Donat F, Carayon P, Thurneyssen O, Pailhon V, Emonds-Alt X, Soubrié P, Le Fur G. (1995) Functional characterization of the nonpeptide neurokinin3 (NK3) receptor antagonist, SR142801 on the human NK3 receptor expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther, 274 (1): 148-54. [PMID:7616392]

74. Panocka I, Massi M, Lapo I, Swiderski T, Kowalczyk M, Sadowski B. (2001) Antidepressant-type effect of the NK3 tachykinin receptor agonist aminosenktide in mouse lines differing in endogenous opioid system activity. Peptides, 22 (7): 1037-42. [PMID:11445231]

75. Pasichnichenko OM, Skok VI. (1999) [The effect of SR 142801, a blocker of tachykinin NK-3 receptors, on synaptic transmission in the rat caudal mesenteric ganglion]. Fiziol Zh, 45 (4): 55-60. [PMID:10474803]

76. Pinnock RD, Suman-Chauhan N, Chung FZ, Webdale L, Madden Z, Hill DR, Woodruff GN. (1994) Characterization of tachykinin mediated increases in [Ca2+]i in Chinese hamster ovary cells expressing human tachykinin NK3 receptors. Eur J Pharmacol, 269 (1): 73-8. [PMID:7530208]

77. Polidori C, Pompei P, Ciccocioppo R, de Caro G, Massi M. (1996) Effects of the selective tachykinin NK3 receptor agonist NH2-senktide on intraoral intake and taste reactivity responses elicited by NaCl in sodium-replete rats. Regul Pept, 66 (1-2): 101-4. [PMID:8899901]

78. Preston Z, Richardson PJ, Pinnock RD, Lee K. (2000) NK-3 receptors are expressed on mouse striatal gamma-aminobutyric acid-ergic interneurones and evoke [(3)H] gamma-aminobutyric acid release. Neurosci Lett, 284 (1-2): 89-92. [PMID:10771169]

79. Ribeiro SJ, Teixeira RM, Calixto JB, De Lima TC. (1999) Tachykinin NK(3)receptor involvement in anxiety. Neuropeptides, 33: 181-188. [PMID:10657489]

80. Saigo A, Takano Y, Matsumoto T, Tran M, Nakayama Y, Saito R, Yamada K, Kamiya H. (1993) Central administration of senktide, a tachykinin NK-3 agonist, has an antidiuretic action by stimulating AVP release in water-loaded rats. Neurosci Lett, 159 (1-2): 187-90. [PMID:7505413]

81. Sakurada T, Yamada T, Sakurada S, Kisara K, Ohba M. (1989) Substance P analogues containing D-histidine antagonize the behavioural effects of intrathecally co-administered substance P in mice. Eur J Pharmacol, 174 (2-3): 153-60. [PMID:2483548]

82. Sandoval-Guzmán T, Rance NE. (2004) Central injection of senktide, an NK3 receptor agonist, or neuropeptide Y inhibits LH secretion and induces different patterns of Fos expression in the rat hypothalamus. Brain Res, 1026 (2): 307-12. [PMID:15488494]

83. Sarau HM, Feild JA, Ames RS, Foley JJ, Nuthulaganti P, Schmidt DB, Buckley PT, Elshourbagy NA, Brawner ME, Luttmann MA et al.. (2001) Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor. Eur J Pharmacol, 413 (2-3): 143-50. [PMID:11226387]

84. Sarau HM, Griswold DE, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Webb EF, Martin LD et al.. (2000) Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist. J Pharmacol Exp Ther, 295 (1): 373-81. [PMID:10992004]

85. Sarau HM, Griswold DE, Potts W, Foley JJ, Schmidt DB, Webb EF, Martin LD, Brawner ME, Elshourbagy NA, Medhurst AD et al.. (1997) Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther, 281 (3): 1303-11. [PMID:9190866]

86. Schmid G, Carità F, Bonanno G, Raiteri M. (1998) NK-3 receptors mediate enhancement of substance P release from capsaicin-sensitive spinal cord afferent terminals. Br J Pharmacol, 125 (4): 621-6. [PMID:9831894]

87. Shafton AD, Bogeski G, Kitchener PD, Lewis VA, Sanger GJ, Furness JB. (2004) Effects of the peripherally acting NK receptor antagonist, SB-235375, on intestinal and somatic nociceptive responses and on intestinal motility in anaesthetized rats. Neurogastroenterol Motil, 16 (2): 223-31. [PMID:15086876]

88. Shigemoto R, Yokota Y, Tsuchida K, Nakanishi S. (1990) Cloning and expression of a rat neuromedin K receptor cDNA. J Biol Chem, 265 (2): 623-8. [PMID:2153106]

89. Shughrue PJ, Lane MV, Merchenthaler I. (1996) In situ hybridization analysis of the distribution of neurokinin-3 mRNA in the rat central nervous system. J Comp Neurol, 372 (3): 395-414. [PMID:8873868]

90. Smith ME, Flynn FW. (1999) Intraventricular injections of tachykinin NK3 receptor agonists affect salt intake. A shift in taste intensity?. Ann N Y Acad Sci, 897: 432-5. [PMID:10676471]

91. Smith PW, Wyman PA, Lovell P, Goodacre C, Serafinowska HT, Vong A, Harrington F, Flynn S, Bradley DM, Porter R et al.. (2009) New quinoline NK3 receptor antagonists with CNS activity. Bioorg Med Chem Lett, 19 (3): 837-40. [PMID:19117759]

92. Stables JM, Beresford IJ, Arkinstall S, Ireland SJ, Walsh DM, Seale PW, Ward P, Hagan RM. (1994) GR138676, a novel peptidic tachykinin antagonist which is potent at NK3 receptors. Neuropeptides, 27 (6): 333-41. [PMID:7534879]

93. Stoessl AJ, Brackstone M, Rajakumar N, Gibson CJ. (1995) Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist. Brain Res, 700 (1-2): 115-20. [PMID:8624700]

94. Stoessl AJ, Dourish CT, Iversen SD. (1988) The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation. Psychopharmacology (Berl.), 95 (4): 502-6. [PMID:2463651]

95. Stoessl AJ, Dourish CT, Iversen SD. (1988) The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats. Br J Pharmacol, 94 (2): 285-7. [PMID:2456111]

96. Stoessl AJ, Dourish CT, Young SC, Williams BJ, Iversen SD, Iversen LL. (1987) Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse. Neurosci Lett, 80 (3): 321-6. [PMID:2446214]

97. Stoessl AJ, Hill DR. (1990) Autoradiographic visualization of NK-3 tachykinin binding sites in the rat brain, utilizing [3H]senktide. Brain Res, 534 (1-2): 1-7. [PMID:1705846]

98. Stoessl AJ, Szczutkowski E, Glenn B, Watson I. (1991) Behavioural effects of selective tachykinin agonists in midbrain dopamine regions. Brain Res, 565 (2): 254-62. [PMID:1668812]

99. Stratowa C, Machat H, Burger E, Himmler A, Schafer R, Spevak W, Weyer U, Wiche-Castanon M, Czernilofsky AP. (1995) Functional characterization of the human neurokinin receptors NK1, NK2, and NK3 based on a cellular assay system. J Recept Signal Transduct Res, 15 (1-4): 617-30. [PMID:8903968]

100. Sundelin JB, Provvedini DM, Wahlestedt CR, Laurell H, Pohl JS, Peterson PA. (1992) Molecular cloning of the murine substance K and substance P receptor genes. Eur J Biochem, 203: 625-631. [PMID:1370937]

101. Takano Y, Nakayama Y, Matsumoto T, Saito R, Kamiya HO. (1993) The mechanism of central pressor actions of tachykinin NK-3 receptor in the paraventricular nucleus of the hypothalamus in rats. Regul Pept, 46 (1-2): 360-3. [PMID:7692537]

102. Tian Y, Wu LH, Oxender DL, Chung FZ. (1996) The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J Biol Chem, 271 (34): 20250-7. [PMID:8702757]

103. Tooney PA, Au GG, Chahl LA. (2000) Localisation of tachykinin NK1 and NK3 receptors in the human prefrontal and visual cortex. Neurosci Lett, 283 (3): 185-8. [PMID:10754218]

104. Tooney PA, Au GG, Chahl LA. (2000) Tachykinin NK1 and NK3 receptors in the prefrontal cortex of the human brain. Clin Exp Pharmacol Physiol, 27 (11): 947-9. [PMID:11071316]

105. Tremblay L, Kemel ML, Desban M, Gauchy C, Glowinski J. (1992) Distinct presynaptic control of dopamine release in striosomal- and matrix-enriched areas of the rat striatum by selective agonists of NK1, NK2, and NK3 tachykinin receptors. Proc Natl Acad Sci USA, 89 (23): 11214-8. [PMID:1280822]

106. Vannucchi MG, Faussone-Pellegrini MS. (2000) NK1, NK2 and NK3 tachykinin receptor localization and tachykinin distribution in the ileum of the mouse. Anat Embryol, 202 (3): 247-55. [PMID:10994997]

107. Wang H, Zhang YQ, Ding YQ, Zhang JS. (2002) Localization of neurokinin B receptor in mouse gastrointestinal tract. World J Gastroenterol, 8: 172-175. [PMID:11833097]

108. Wormser U, Laufer R, Hart Y, Chorev M, Gilon C, Selinger Z. (1986) Highly selective agonists for substance P receptor subtypes. EMBO J, 5 (11): 2805-8. [PMID:2431898]

109. Zaratin P, Angelici O, Clarke GD, Schmid G, Raiteri M, Carità F, Bonanno G. (2000) NK3 receptor blockade prevents hyperalgesia and the associated spinal cord substance P release in monoarthritic rats. Neuropharmacology, 39 (1): 141-9. [PMID:10665827]

110. Zerari F, Karpitskiy V, Krause J, Descarries L, Couture R. (1997) Immunoelectron microscopic localization of NK-3 receptor in the rat spinal cord. Neuroreport, 8 (12): 2661-4. [PMID:9295096]

Contributors

Show »

How to cite this page